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Abstract
Background
Pancreatic pseudocysts (PC) and walled-off necrosis (WON) are common complications of
severe pancreatitis. Endoscopic ultrasound (EUS)-guided drainage has replaced surgery as
the standard treatment for PC/WON. We developed a novel lumen-apposing metal stent
(LAMS) with an anti-reflux valve to prevent infectious complications caused by food reflux
into the cyst cavity. This retrospective study investigated the efficacy and safety of EUS-
guided drainage using this LAMS.
Methods
We investigated and compared the treatment outcomes and complications rates between
EUS-guided drainage using a novel LAMS (n = 10) versus plastic stents (n = 18) from
December 2013 to October 2016. Technical success was defined as successful stent place-
ment without immediate complications. Clinical success was defined as resolution of the
PC/WON and disappearance of symptoms.
Results
Among 10 patients in LAMS group, 4 patients had complicated PC and 6 patients had
WON. In the plastic stent group, 15 and 3 patients had PC and WON, respectively. The
median fluid collection size before treatment was 82.5 (interquartile range [IQR], 60.75–
118.25) mm and 92.0 (IQR, 75.75–130.25) mm in the LAMS and plastic stent groups,
respectively. There were no statistically significant differences in technical success rates
(90% vs. 94.4%; p = 0.999), clinical success rates (80% vs. 77.8%; p = 0.999), and compli-
cation rates (20% vs. 27.8%; p = 0.999) between the two groups.
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Conclusions
Treatment outcomes of EUS-guided drainage using a novel LAMS were feasible despite the
significantly high proportion of WON. The LAMS allowed acceptable treatment outcomes for
EUS-guided drainage.
Introduction
Severe acute pancreatitis and chronic pancreatitis result in local complications in the form of
peripancreatic fluid collections (PFC). According to the revised Atlanta classification, local
complications of pancreatitis are classified as acute PFC, pancreatic pseudocyst (PC), acute
necrotic collection, and walled-off necrosis (WON) [1]. Among these, PC and WON are
encapsulated fluid collections with or without solid necrotic components that usually occur
after more than 4 weeks since the onset of pancreatitis. Most PC and WON cases remain
asymptomatic or resolve spontaneously. However, treatment is required when symptoms and
complications, such as pain, biliary obstruction, or infection occur [2].
Previously, surgical interventions, such as drainage and open necrosectomy, were the only
modalities of treatment, but these invasive procedures are associated with high rates of compli-
cations and mortality [3, 4]. With recent technological advances, endoscopic ultrasound
(EUS)-guided drainage has replaced surgical treatment and has become the standard treat-
ment [5]. The endoscopic approach has shown favorable treatment outcomes for PC and
WON [6]. Studies have reported that success rates of EUS-guided fluid collection drainage and
endoscopic necrosectomy range from 84% to 94% and 68% to 91%, respectively [7–9]. In addi-
tion to success rates, EUS-guided treatment has benefits regarding mortality, cost, hospital
stay, and quality of life [10, 11].
EUS-guided treatment of PC and WON consists of fistula tract formation between the
lesion and stomach (cystogastrostomy) or duodenum (cystoduodenostomy), stent placement
via the fistula tract, and transluminal drainage. Therefore, for successful treatment, it is impor-
tant for stent patency to be maintained without obstruction or migration throughout the treat-
ment period. To date, a plastic stent has been used for EUS-guided drainage procedures.
However, it is susceptible to obstruction and migration, and multiple stents are required to
maintain adequate tract size for treating WON with solid necrotic debris [12]. The practice of
placing multiple plastic stents is a time-consuming and difficult procedure because collapse of
the cyst cavity and change of the tangential axis may occur after deployment of the first stent
[13]. In recent years, metal stents have been developed to overcome the limitations of plastic
stent with small calibers. The fully covered self-expanding metal stent (FCSEMS) and specially
designed lumen-apposing metal stent (LAMS) are examples of these stents [14]. LAMS is a
recently introduced novel “barbell-shaped” stent with larger calibers that allow for longer
patency, reduced rates of occlusion, and decreased probability of secondary infections. Fur-
ther, owing to the presence of bilateral anchor flanges, LAMS has anti-migrating ability and
ability to oppose the PFC wall to the gastric or duodenal wall [15, 16]. However, according to a
recent study, there is not enough current evidence to support the superiority of metal stents
for transmural drainage of PFC compared to plastic stent. Therefore, further investigations of
novel devices are needed [17].
We developed a novel fully covered LAMS with an anti-migration flap and anti-reflux valve
to prevent complications such as stent migration and reflux of bowel contents, thereby
improving stent patency and minimizing the fasting period after the procedure.
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Materials and methods
Patients
We retrospectively reviewed patients who underwent EUS-guided drainage (cystogastrostomy
or cystoduodenostomy) using a novel LAMS to treat PC or WON at Severance Hospital from
December 2013 to October 2016. This study was approved by the local Institutional Review
Board (4-2019-0114) and was conducted in accordance with the principles set forth in the Dec-
laration of Helsinki. Given its retrospective nature, written informed consent was not required
by the board to access the clinical data. Indications for EUS-guided drainage were infected PC
or WON, gastric outlet obstruction, biliary obstruction, and intractable symptoms such as
abdominal pain. The size of the PC or WON itself was not an indication for the procedure
During this period, 10 and 18 patients underwent EUS-guided drainage using the novel LAMS
(LAMS group) and conventional plastic stent (PS group), respectively. All pertinent data
including demographics, lesion site, symptom improvement, duration of stent placement, and
treatment-related adverse events were investigated. Technical success was defined as successful
stent placement without immediate adverse events. Clinical success was defined as resolution
of the PC/WON and the disappearance of symptoms.
Materials
The novel HANARO stent (M.I.Tech, Seoul, South Korea) used in this study is a specially
designed LAMS. This novel LAMS was designed to reduce side effects and improve treatment
results of EUS-guided drainage.
The LAMS has a structure of weaving nitinol mesh with full silicone covering. Stent dimen-
sions of 10 mm diameter and length of 40 mm and 50 mm, were applied in accordance with
the environment between the gastrointestinal lumen and PFC. For anti-migration, both ends
of the stent are flared and additional 3 flaps are located on both sides. The S-type valve is
applied to the internal path of the stent for anti-reflux. The function of the S-type valve is to
drain the fluid and debris in the PFC into the gastrointestinal tract and prevent food reflux.
The proximal end of the stent has a retrieval lasso for smooth stent removal from body (Fig 1A
and 1B). The delivery device of 10.2 Fr uses a braided catheter to maximize flexibility and pre-
vent kinking. Although anti-migration flaps and valves were added to this novel LAMS, con-
ventional 10.2 Fr could be used to deploy the stent instead of a thicker delivery device.
Therefore, additional friction was not required to pass through the accessory channel of the
endoscope (Fig 2A and 2B).
The stent and delivery system used in this study was approved by the Korean government
(Ministry of Food and Drug Safety, Approval No. 04–1242) and commercialized and sterilized
using a standardized manufacturing process.
Procedure
All procedures were performed by skilled endoscopists (M.J.C., J.Y.P., S.B., and S.W.P.).
Patients were administered conscious sedation with midazolam and in case of poor sedation
with midazolam alone, deep sedation was performed using propofol under cardiopulmonary
monitoring. EUS GF-UCT260 (Olympus, Tokyo, Japan) scopes were used in all cases. Color
Doppler imaging was used to identify interposed vessels, and each lesion was punctured under
EUS guidance with a 19-guage EchoTip needle (Cook Medical, Bloomington, IN, USA). After
the puncture, a straight VisiGlide (Olympus, Tokyo, Japan) guidewire was inserted into the
lesion. The puncture site was dilated using a Soehendra dilator (Cook Medical), followed by
balloon dilatation using a Hurricane balloon (Boston Scientific, Marlborough, MA, USA) if
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needed. Finally, the HANARO stent (M.I.Tech) was deployed via 10.2Fr delivery system
through the scope (Fig 3). The LAMS was removed endoscopically after resolution of PC and
WON using follow-up computed tomography approximately 6 to 8 weeks after the procedure.
Statistical analysis
All statistical analyses were performed using SPSS for Windows version 23.0 (IBM, Armonk,
NY, USA). Categorical variables were described as patient number and proportions for all
patients. Continuous variables were described as medians and interquartile ranges.
Results
Treatment outcome of LAMS
The demographics, etiology, treatment details, and outcomes of all patients in LAMS group
are summerized in Table 1. Ten patients (4 with PC and 6 with WON) underwent EUS-guided
treatment using LAMS. The median size of fluid collection before treatment was 82.5 mm
(interquartile range [IQR], 60.75–118.25 mm), and the median duration of stent placement
was 47 days (IQR, 25.75–79.50 days).
LAMS were placed successfully in 9 of 10 patients (unsuccessful placement in patient 5;
90% technical success rate). Clinical success was achieved by 8 patients (80%). One patient
who did not achieve clinical success (patient #6) needed additional endoscopic necrosectomy
after removal of the initially deployed LAMS. Adverse events were observed in only 2 patients.
One patient experienced peritonitis due to immediate migration (patient #5). In this patient,
LAMS was immediately removed and the gastric mucosa was sealed by endoscopic clipping.
The patient recovered completely after non-surgical conservative care that included fasting,
nasogastric tube insertion, and administration of broad-spectrum antibiotics. The other
patient (patient #4) had fever for 3 days after the procedure but it improved after using
antibiotics.
Fig 1. The lumen-apposing metal stent with an anti-reflux S-valve and anti-migration flaps (A) and schematic illustration of the anti-reflux S-
valve inside the lumen of the lumen-apposing metal stent (B). This S-valve prevents the reflux of food from the gastrointestinal tract to the pancreatic
pseudocyst/walled-off necrosis.
https://doi.org/10.1371/journal.pone.0221812.g001
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For most patients, oral feeding was resumed within 2 days after the procedure. Only 2
patients required more than a 1-week fasting period: 1 patient with an immediate complication
and 1 with severe necrotizing pancreatitis. Patients who achieved clinical success did not
require additional treatment to treat PC or WON. Removal of all LAMS was performed with-
out adverse events.
Fig 2. The 10.2 Fr delivery system for the novel lumen-apposing metal stent. Its gross appearance (A) and name
and function of each part (B).
https://doi.org/10.1371/journal.pone.0221812.g002
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Comparison with plastic stent
Treatment outcomes and complications of EUS-guided drainage using LAMS were compared
with those of EUS-guided drainage using plastic stent (n = 18) during the same period
(Table 2). When patients were classified according to etiology, there was a significantly higher
proportion of WON patients in the LAMS group than in the plastic stent group (60% vs.
16.7%; p = 0.035). There were no statistically significant differences in age, sex, or median size
Fig 3. Endoscopic ultrasound (EUS)-guided pseudocyst drainage using the lumen-apposing metal stent (LAMS).
(A) The lesion was punctured under EUS (Doppler) guidance with a 19-gauge EchoTip needle (B). (C) A guidewire
was inserted in the lesion. (D) The puncture site was dilated using a Soehendra dilator. (E) Balloon dilatation using a
Hurricane balloon. (F) The LAMS was deployed through the scope.
https://doi.org/10.1371/journal.pone.0221812.g003
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Table 1. Data of all patients treated with LAMS.
Age/
Sex
Etiology Reason for
stent
placement
Lesion size
at
diagnosis
(mm)
Duration of
stent
placement
(days)
Lesion
size at
follow-
up
(mm)
Technical
success
Clinical
success
Adverse
event
Duration
of NPO
(days)
Additional
treatment
Hospital
days after
stent
placement
Procedure
time (min.)
1 33/F PC Symptom 61 42 0 Yes Yes No 2 No 14 12
2 35/
M
WON Infection 64 30 0 Yes Yes No 3 No 11 29
3 43/
M
WON Symptom 92 355 22 Yes Yes No 1 No 23 29
4 59/
M
PC Symptom 143 71 21 Yes Yes Fever 1 No 12 36
5 58/
M
PC Infection 48 1 23 No No Peritonitis 11 Clipping &
Nasogastric
tube insertion
27 14
6 69/
M
WON Infection 214 13 220 Yes No No 1 Necrosectomy 108 65
7 42/
M
PC Gastric
outlet
obstruction
110 90 0 Yes Yes No 1 No 4 25
8 55/
M
WON Symptom 60 40 0 Yes Yes No 1 No 3 22
9 55/
M
WON Symptom 73 52 0 Yes Yes No 1 No 8 32
10 50/
M
WON Symptom 93 76 28 Yes Yes No 8 No 29 43
https://doi.org/10.1371/journal.pone.0221812.t001
Table 2. Comparison of treatment data between LAMS and plastic stent.
Treated with LAMS (n = 10) Treated with plastic stents (n = 18) p-value
Age, years 52.50 (40.25–58.25) 48.00 (41.50–62.00) 0.981
Sex 0.375
Male 9 (90%) 13 (72.2%)
Female 1 (10%) 5 (27.8%)
Etiology 0.035
PC 4 (40%) 15 (83.3%)
WON 6 (60%) 3 (16.7%)
Lesion size at diagnosis, mm 82.50 (60.75–118.25) 92.00 (75.75–130.25) 0.524
Duration of stent placement, days 47 (25.75–79.50) 55 (30.75–101.50) 0.621
Technical success, n(%) 9 (90.0%) 17 (94.4%) 0.999
Clinical success, n(%) 8 (80.0%) 14 (77.8%) 0.999
Complication, n(%) 2 (20.0%) 5 (27.8%) 0.999
NPO duration, Days 2 (1–4.25) 2 (1–3) 0.689
HOD after treatment, Days 13 (7–27.5) 4.5 (4–11.25) 0.057
Procedure time, min 29 (20–37.75) 37 (33–48.5) 0.051
Variables are expressed as median (IQR) or n (%).
Abbreviation: NPO, Nulla per os (nothing by mouth); HOD, Hospital days
https://doi.org/10.1371/journal.pone.0221812.t002
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of fluid collection before treatment (82.5 mm vs. 92.0 mm; p = 0.524). There were no statisti-
cally significant differences in the median duration of stent placement (47 days vs. 55 days;
p = 0.621), technical success rates (90% versus 94.4%; p = 0.999), clinical success rates (80% vs.
77.8%; p = 0.999), and adverse event rates (20% vs. 27.8%; p = 0.999). There was a trend toward
shorter procedure times for the LAMS group than for the PS group (29 minutes vs. 37 minutes;
p = 0.051), whereas the fasting periods after treatment (2.0 days vs. 2.0 days; p = 0.689) were
not significantly different between both groups. In the plastic stent group, acute peritonitis
developed in 2 patients, gastrointestinal bleeding developed in 1 patient, and stent self-migra-
tion (after resolution of fluid collection) developed in 2 patients.
Discussion
To date, double-pigtail plastic stent have been used for EUS-guided drainage for PC and
WON. EUS-guided drainage using the plastic stent remains the standard treatment for PC
because evidence indicating the superiority of metal stents for treating PC is not yet sufficient.
The overall efficacy of the plastic stent for treating PC exceeds 90% [10, 18] the thin PC wall
may be damaged by the tip of the metal stent owing to rapid collapse of the PC when it is
treated with large-caliber metal stents. However, the efficacy of the plastic stent for WON
treatment is significantly lower [19]. Because the plastic stent has a relatively small caliber (7 Fr
or 10 Fr), the presence of solid debris in WON decreases drainage and increases the risk of sec-
ondary infection due to insufficient drainage of solid debris [19, 20].
Biliary or esophageal metal stents with large calibers were used to overcome the disadvan-
tages of PS, but longer protrusions on both sides of the stents can cause contact ulceration in
the bowel and late-phase bleeding [21]. There is also a risk of migration because the conven-
tional straight esophageal and biliary metal stents have no anti-migration system such as flare
ends and anti-migration flaps [22]. Moreover, although under-reported in the current litera-
tures, there is a risk of stent obstruction or secondary infection due to retrograde reflux of food
contents [23, 24]. Therefore, the specially designed LAMS was introduced for safer and more
effective treatment of WON. Although controversies exist regarding the choice of stent for
WON, recent studies have verified the superiority of the LAMS compared with the plastic
stent for the treatment of WON. The use of LAMS was associated with fewer endoscopic ses-
sions, fewer adverse events, shorter hospital stay, and a reduced need for salvage surgery [20,
25].
In this study population, both plastic stent and LAMS were used to treat PC/WON. When
selecting a stent, LAMS was considered if patients had a large PFC requiring repeated drainage
or showed walled-off necrosis in radiologic findings. In accordance with the previous studies,
PC patients in the plastic stent group showed treatment success rate of 80% (12 in 15). How-
ever, 2 cases of stent migration and 3 cases of major adverse events (peritonitis, bleeding) were
seen in the plastic stent group; however, stent migration after successful deployment was not
observed in the LAMS group. Although this is a small pilot study, it is noteworthy that the
newly designed LAMS did not differ in safety and efficacy when compared to plastic stent. The
technical improvement applied to this LAMS prevented unwanted stent migration and cystic
wall injury caused by metal stent tip, and there were no adverse events during the early
resumption of oral feeding. Large scale studies are warranted to ensure that the technical
improvements in stent structure and delivery system can minimize the chances of complica-
tions (i.e. migration, bleeding, etc.) and shorten the procedure time of EUS-guided drainage.
Previous clinical trials that verified the efficacy and safety of metal stents for PFC drainage
are described by Ang et al [26]. When PFC was treated using a fully covered self-expandable
metallic stent designed for drainage of PFC, technical success rates of 91% to 100%, clinical
A novel LAMS with an anti-reflux valve for EUS-guided drainage of peripancreatic fluid collection
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success rates of 76% to 100% were reported; however, the incidence of complications, such as
bleeding (1% to 7%), perforation (1% to 2%), stent migration (1% to 6%), and infection (1% to
11%) was quite low [15, 16, 21, 22, 27–30]. Specially designed metal stents showed better out-
comes than plastic stents in several studies, especially in the treatment of WON [20, 25, 31]. In
our study using a novel LAMS, a high technical success rate (90%) and high clinical success
rate (80%) were achieved, as in previous studies. The complication rate was also low; 1 case of
fever and 1 case of immediate stent migration occurred. Therefore, this study outcome can
support the clinical utility and safety of the use of LAMS in the treatment of WON and PC,
which is specially designed for PFC drainage.
The presence of the anti-reflux valve inside the lumen and anti-migration flaps on each side
are the distinguishing features of this novel LAMS. Several studies demonstrate the effect of
preventing reflux when anti-reflux S-valve is applied to the metal stent [32–34]. Gastroesopha-
geal reflux could be prevented by the esophageal metal stent with S-valve and longer duration
of biliary metal stent could be achieved by preventing food reflux through the S-valve. Based
on these studies, we conducted this pilot study and found a possibility of clinical improvement.
In a previous study by Yamamoto et al. using a modified fully covered self-expanding metal
stent, most patients fasted for a period of at least 3 days; however, in our study, most patients
resumed oral feeding within 2 days, and there were no side effects related to food reflux [27]. A
shorter duration of parenteral nutrition can reduce side effects and improve general patient
conditions and compliance [35]. In addition, the presence of the anti-migration flap prevents
stent migration and more accurately confirms the location and deployment of the distal flap
on EUS or fluoroscopy during stent deployment.
This study had several limitations. First, it was a retrospective study with a small number of
patients. Moreover, there was no precise planning for the long-term follow-up. Therefore,
most patients were not evaluated after fluid collections resolved. As such, recurrence and late-
phase complications might have been underestimated. Second, the patients were not randomly
assigned to each group, and 10 patients cannot represent all the PC/WON patients. Thus,
selection bias and sampling bias could have occurred. Further well-designed prospective stud-
ies are needed to validate these findings.
In conclusion, EUS-guided drainage using this novel LAMS demonstrated clinical utility to
treat PFC with lower complication rates and acceptable treatment outcomes.
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